A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD 1 and LAG 3, in patients with unresectable or metastatic neoplasms.
MGD-013
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD 1 and LAG 3, in patients with unresectable or metastatic neoplasms. ### Output: MGD-013